To include your compound in the COVID-19 Resource Center, submit it here.

Exelixis deal

Exelixis partnered with the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) for the clinical development of Exelixis' cabozantinib in several

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE